Key result
Levosimendan administration in children with severe heart failure improved ejection fraction from 29.8% to 40.5% and allowed for catecholamine reduction.
Why the study?
Does Levosimendan improve ventricular function and reduce catecholamine requirements in critically ill children with severe heart failure?
Cohort (n=15)
No
Does Levosimendan improve ventricular function and reduce catecholamine requirements in critically ill children with severe heart failure?
Levosimendan appears safe in children with severe heart failure and may facilitate the reduction of catecholamine support while improving myocardial performance, particularly in acute heart failure.
Answers are grounded in this paper and cite their sources.
May support levosimendan in severe pediatric HF; leaves open confirmation in randomized trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Crossland et al. (2006) conducted a cohort in Severe myocardial dysfunction secondary to end-stage or acute heart failure (n=15). Levosimendan vs. Pre-Levosimendan baseline was evaluated on Ejection fraction (p=0.015). Levosimendan administration in children with severe heart failure improved ejection fraction from 29.8% to 40.5% and allowed for catecholamine reduction.
Synapse has enriched 10 related papers. Consider them for comparative context: